Simulations Plus Releases Updated QST Software DILIsym Version X To Investigate And Predict Drug-Induced Liver Injury
Portfolio Pulse from Benzinga Newsdesk
Simulations Plus has released an updated version of its QST software, DILIsym Version X, which is designed to investigate and predict drug-induced liver injury.
August 01, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Simulations Plus has launched DILIsym Version X, an updated QST software aimed at predicting drug-induced liver injury, which could enhance its product offerings and attract more clients in the pharmaceutical and biotech sectors.
The release of DILIsym Version X is a significant product update that could attract more clients from the pharmaceutical and biotech industries, potentially increasing revenue and market share for Simulations Plus.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100